We agree it is difficult to draw certain conclusions given the evidence of today, though in our opinion, different driver mutations (such as EGFR or KRAS mutations or ALK or ROS1 rearrangements, like in our cases 4 and 6) probably quite strongly support synchronous/metachronous tumours. Here, EGFR is linked to neoplasm.